Skip to main content

Clinical Trials Using Durvalumab

Review the clinical trials studying durvalumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-84 of 84

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Status: Active
Location: 2 locations
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Status: Active
Location: See ClinicalTrials.gov
Risk-Adapted, Proteomic-Guided (PROphet CB, and CARG-TT) Systemic Therapy for the Treatment of Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer
Status: Approved
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Emavusertib in Combination with Cisplatin, Gemcitabine, and Durvalumab for the Treatment of Advanced Unresectable or Metastatic Biliary Tract Cancer
Status: Approved
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Tremelimumab with Durvalumab to Increase Immune Cells in Patients with Resectable or Locally Advanced Unresectable MSI-Stable or pMMR Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma with ARID1A Mutations
Status: Approved
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: 3 locations
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients with Non-Small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: 193 locations
Stereotactic Body Radiotherapy in Combination with Durvalumab, Cisplatin or Carboplatin, and Etoposide for Treatment of Refractory Extensive Stage Small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
NKTR-255 in Restoring Lymphocytes after Chemoradiotherapy for the Treatment of Non-Small Cell Lung Cancer, RESCUE Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas